cardiovascular benefits of glp 1 agonists GLP-1 receptor and outcome trials: An update Bridging the gap between GLP1-receptor

Gut-brain communication by distinct sensory neurons differently controls feeding and glucose metabolism

The next wave dual and triple agonists (GLP-1 + GIP + glucagon: tirzepatide, retatrutide, survodutide) are showing superior fat loss, better hepatic outcomes, and potentially preserved lean mass

Monitoring your progress after switching What you measure determines what you can improve

Regular follow-up appointments and adherence to monitoring protocols are essential to ensure the safe and effective use of these medications

In a post hoc analysis of the SURPASS-1 trial involving patients with T2DM, the percentage increase in adiponectin levels from baseline ranged from 16% to 23% with tirzepatide compared to a decrease of 0.2% with placebo at week 40 (190)